• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

P16和Ki67免疫染色可降低肛管上皮内瘤变(AIN)诊断与分级中的观察者内及观察者间差异。

P16 and Ki67 Immunostains Decrease Intra- and Interobserver Variability in the Diagnosis and Grading of Anal Intraepithelial Neoplasia (AIN).

作者信息

Walts Ann E, Lechago Juan, Hu Bing, Shwayder Marybeth, Sandweiss Lynn, Bose Shikha

机构信息

Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA.

出版信息

Clin Med Pathol. 2008;1:7-13. doi: 10.4137/cpath.s501. Epub 2008 Feb 9.

DOI:10.4137/cpath.s501
PMID:21876646
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3159996/
Abstract

BACKGROUND

Significant variation is reported in the diagnosis of HPV-associated AIN. We previously observed that band-like positivity for p16 in >90% of contiguous cells coupled with Ki67 positivity in >50% of lesional cells is strongly associated with high grade AIN. This study was undertaken to determine if addition of p16 and Ki67 immunostaining would reduce inter- and intraobserver variability in diagnosis and grading of AIN.

DESIGN

H&E stained slides of 60 anal biopsies were reviewed by three pathologists and consensus diagnoses were achieved: 25 negative, 12 low (condyloma and/or AIN I) and 23 high (9 AIN II and 14 AIN III) grade lesions. The H&E stained slides were diagnosed independently by three additional ("participant") pathologists. Several weeks later they re-examined these slides in conjunction with corresponding p16 and Ki67 immunostains.

RESULTS

Addition of p16 and Ki67 immunostains reduced intra- and interobserver variability, improved concurrence with consensus diagnoses and reduced two-step differences in diagnosis. Negative and high grade AIN diagnoses showed the most improvement in concurrence levels.

CONCLUSION

Addition of p16 and Ki67 immunostains is helpful in the diagnosis and grading of AIN.

摘要

背景

据报道,人乳头瘤病毒(HPV)相关的肛门上皮内瘤变(AIN)的诊断存在显著差异。我们之前观察到,超过90%的连续细胞中p16呈带状阳性,同时超过50%的病变细胞中Ki67呈阳性,这与高级别AIN密切相关。本研究旨在确定添加p16和Ki67免疫染色是否会减少AIN诊断和分级中观察者间和观察者内的变异性。

设计

三位病理学家对60份肛门活检的苏木精-伊红(H&E)染色切片进行了复查,并达成了共识诊断:25份为阴性,12份为低级别(湿疣和/或AIN I),23份为高级别(9份AIN II和14份AIN III)病变。另外三位(“参与”)病理学家独立诊断H&E染色切片。几周后,他们结合相应的p16和Ki67免疫染色重新检查了这些切片。

结果

添加p16和Ki67免疫染色减少了观察者内和观察者间的变异性,提高了与共识诊断的一致性,并减少了诊断中的两级差异。阴性和高级别AIN诊断在一致性水平上改善最为明显。

结论

添加p16和Ki67免疫染色有助于AIN的诊断和分级。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c2d/3159996/b1289690342b/cpath-1-2008-007f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c2d/3159996/6e23e64a9c79/cpath-1-2008-007f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c2d/3159996/b1289690342b/cpath-1-2008-007f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c2d/3159996/6e23e64a9c79/cpath-1-2008-007f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c2d/3159996/b1289690342b/cpath-1-2008-007f2.jpg

相似文献

1
P16 and Ki67 Immunostains Decrease Intra- and Interobserver Variability in the Diagnosis and Grading of Anal Intraepithelial Neoplasia (AIN).P16和Ki67免疫染色可降低肛管上皮内瘤变(AIN)诊断与分级中的观察者内及观察者间差异。
Clin Med Pathol. 2008;1:7-13. doi: 10.4137/cpath.s501. Epub 2008 Feb 9.
2
P16 and Ki67 immunostaining is a useful adjunct in the assessment of biopsies for HPV-associated anal intraepithelial neoplasia.P16和Ki67免疫染色在评估与HPV相关的肛门上皮内瘤变活检中是一种有用的辅助手段。
Am J Surg Pathol. 2006 Jul;30(7):795-801. doi: 10.1097/01.pas.0000208283.14044.a9.
3
P16/CDKN2A and Ki-67 enhance the detection of anal intraepithelial neoplasia and condyloma and correlate with human papillomavirus detection by polymerase chain reaction.P16/CDKN2A 和 Ki-67 增强了肛门上皮内瘤变和尖锐湿疣的检测,并与聚合酶链反应检测人乳头瘤病毒相关。
Am J Surg Pathol. 2010 Oct;34(10):1449-55. doi: 10.1097/PAS.0b013e3181f0f52a.
4
Diagnosing Anal Squamous Intraepithelial Lesions With and Without p16: An Interobserver Variability Study.诊断伴有和不伴有 p16 的肛门鳞状上皮内病变:一项观察者间变异性研究。
J Low Genit Tract Dis. 2020 Jan;24(1):69-74. doi: 10.1097/LGT.0000000000000500.
5
p16 Improves interobserver agreement in diagnosis of anal intraepithelial neoplasia.p16可提高肛门上皮内瘤变诊断中的观察者间一致性。
J Low Genit Tract Dis. 2009 Jul;13(3):145-53. doi: 10.1097/LGT.0b013e3181934486.
6
Anal intraepithelial neoplasia: correlation of grade with p16INK4a immunohistochemistry and HPV in situ hybridization.肛管上皮内瘤变:级别与p16INK4a免疫组化及人乳头瘤病毒原位杂交的相关性
Appl Immunohistochem Mol Morphol. 2008 May;16(3):215-20. doi: 10.1097/PAI.0b013e3181454a95.
7
Anal intraepithelial neoplasia: a single centre 19 year review.肛管上皮内瘤变:单中心19年回顾
Colorectal Dis. 2014 Oct;16(10):777-82. doi: 10.1111/codi.12679.
8
Presence or Absence of Significant HPVE4 Expression in High-grade Anal Intraepithelial Neoplasia With p16/Ki-67 Positivity Indicates Distinct Patterns of Neoplasia: A Study Combining Immunohistochemistry and Laser Capture Microdissection PCR.在 p16/Ki-67 阳性的高级别肛门上皮内瘤变中存在或不存在显著的 HPV E4 表达提示不同的肿瘤发生模式:一项结合免疫组织化学和激光捕获微切割 PCR 的研究。
Am J Surg Pathol. 2018 Apr;42(4):463-471. doi: 10.1097/PAS.0000000000000984.
9
ProEx™ C is a useful ancillary study for grading anal intraepithelial neoplasia alone and in combination with other biomarkers.ProEx™ C是一项有用的辅助研究,可单独对肛管上皮内瘤变进行分级,也可与其他生物标志物联合使用。
APMIS. 2016 Mar;124(3):175-80. doi: 10.1111/apm.12481. Epub 2015 Nov 20.
10
Expression of proliferative biomarkers in anal intraepithelial neoplasia of HIV-positive men.在 HIV 阳性男性的肛门上皮内瘤变中增殖生物标志物的表达。
J Am Acad Dermatol. 2010 Sep;63(3):490-8. doi: 10.1016/j.jaad.2009.08.043. Epub 2009 Dec 16.

引用本文的文献

1
Classifying Anal Intraepithelial Neoplasia 2 Based on LAST Recommendations.根据LAST建议对肛管上皮内瘤变2级进行分类。
Am J Clin Pathol. 2021 May 18;155(6):845-852. doi: 10.1093/ajcp/aqaa188.
2
Expression of microRNAs 16, 20a, 150 and 155 in anal squamous intraepithelial lesions from high-risk groups.高危人群肛门鳞状上皮内病变中 microRNAs 16、20a、150 和 155 的表达。
Sci Rep. 2019 Feb 6;9(1):1523. doi: 10.1038/s41598-018-38378-6.
3
Characterization of topoisomerase II α and minichromosome maintenance protein 2 expression in anal carcinoma.

本文引用的文献

1
Anal intraepithelial neoplasia and other neoplastic precursor lesions of the anal canal and perianal region.肛管及肛周区域的肛门上皮内瘤变及其他肿瘤性前驱病变。
Gastroenterol Clin North Am. 2007 Dec;36(4):969-87, ix. doi: 10.1016/j.gtc.2007.08.001.
2
P16 and Ki67 immunostaining is a useful adjunct in the assessment of biopsies for HPV-associated anal intraepithelial neoplasia.P16和Ki67免疫染色在评估与HPV相关的肛门上皮内瘤变活检中是一种有用的辅助手段。
Am J Surg Pathol. 2006 Jul;30(7):795-801. doi: 10.1097/01.pas.0000208283.14044.a9.
3
Interobserver agreement in the interpretation of anal intraepithelial neoplasia.
拓扑异构酶IIα和微小染色体维持蛋白2在肛管癌中的表达特征
Oncol Lett. 2017 Mar;13(3):1891-1898. doi: 10.3892/ol.2017.5650. Epub 2017 Jan 25.
肛管上皮内瘤变解读中的观察者间一致性
Cancer. 2005 Apr 1;103(7):1447-56. doi: 10.1002/cncr.20927.
4
Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer.肛门癌病因中的人乳头瘤病毒、吸烟及性行为
Cancer. 2004 Jul 15;101(2):270-80. doi: 10.1002/cncr.20365.
5
Interobserver and intraobserver bias exists in the interpretation of anal dysplasia.在肛管发育异常的诊断中存在观察者间和观察者内偏差。
Dis Colon Rectum. 2003 Oct;46(10):1332-6; discussion 1336-8. doi: 10.1007/s10350-004-6744-5.
6
[Preneoplastic anal lesions and anal canal carcinoma].[癌前肛门病变与肛管癌]
Bull Cancer. 2003 May;90(5):405-11.
7
Is anal carcinoma a HAART-related problem?肛门癌是一个与高效抗逆转录病毒治疗(HAART)相关的问题吗?
Eur J Med Res. 2003 Apr 30;8(4):142-6.
8
The 2001 Bethesda System: terminology for reporting results of cervical cytology.2001年贝塞斯达系统:宫颈细胞学检查结果报告术语
JAMA. 2002 Apr 24;287(16):2114-9. doi: 10.1001/jama.287.16.2114.
9
Effect of highly active antiretroviral therapy on the natural history of anal squamous intraepithelial lesions and anal human papillomavirus infection.高效抗逆转录病毒疗法对肛门鳞状上皮内病变及肛门人乳头瘤病毒感染自然史的影响。
J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):422-8. doi: 10.1097/00042560-200112150-00003.
10
Anal squamous intraepithelial lesions in human immunodeficiency virus-positive men and women.人类免疫缺陷病毒阳性男性和女性的肛管鳞状上皮内病变
Semin Oncol. 2000 Aug;27(4):471-9.